On April 21, 2026 Precede Biosciences, a company powering next-generation precision medicine through its comprehensive epigenomic liquid biopsy platform, reported the launch of Precede Bio Insight and the presentation of new data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2026 Annual Meeting, held April 17–22 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Precede Bio Insight is a first-of-its-kind product that decodes genome-wide transcriptional biology from cell-free DNA in just 1 mL of plasma, enabling quantitative inference of gene expression, pathway activity, and cell states with concordance to tissue-based measurements. By simultaneously assessing therapeutic targets, resistance pathways, and tumor lineage programs in a single assay, Insight provides a functional, systems-level view of tumor biology to inform drug development and patient selection.
"Cancer clinical trials enroll close to 300,000 patients annually, yet access to real-time functional tumor biology remains limited, constraining mechanistic insight and the ability to refine therapeutic development strategies," said Rehan Verjee, Chief Executive Officer of Precede Biosciences. "With the launch of Precede Bio Insight, R&D teams can now serially access genome-wide visibility across targets, pathways, and cell states from just 1 mL of plasma, enabling smarter decisions about patient selection, treatment combinations, and sequencing."
The Insight launch is supported by a growing body of clinical evidence, including the three studies presented at AACR (Free AACR Whitepaper) 2026, conducted in collaboration with Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Genentech, and Emory University School of Medicine. Across these studies, profiling from plasma:
Correlated with tissue-based measures of tumor biology, including RNA expression and protein target expression
Enabled multiplexed, quantitative assessment of therapeutically relevant targets and pathways such as DLL3, CEACAM5, and the ER pathway
Captured tumor heterogeneity and lineage plasticity, including continuous states of neuroendocrine differentiation
Predicted response to endocrine therapy, including next-generation SERDs, through a plasma-based functional measure of tumor ER pathway dependence
Provided early pharmacodynamic readout of treatment response
Revealed resistance mechanisms beyond genomic alterations
AACR 2026 Presentations
Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC)
A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms
Data presentations are available in the presentations section of the company website at www.precede.bio.
(Press release, Precede Biosciences, APR 21, 2026, View Source [SID1234664675])